Clinical TrialMay 13, 2026, 07:17 AM
Altimmune's Pemvidutide 48-Week MASH Data Selected for Best of EASL 2026
AI Summary
Altimmune, Inc. announced that analyses of data from its IMPACT Phase 2b clinical trial for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the European Association for the Study of the Liver (EASL) Congress 2026. The company's abstract on 48-week results was selected as "Best of EASL 2026" and will be featured in an oral presentation. Additionally, new 24-week findings, including digital pathology analysis of liver fibrosis regression and cardiovascular measures, will be presented in poster sessions.
Key Highlights
- Altimmune's 48-week IMPACT Phase 2b efficacy and safety data selected for "Best of EASL 2026".
- Oral presentation will highlight 48-week IMPACT efficacy and safety data at EASL Congress 2026.
- Late-breaker abstract features new digital pathology analysis of liver fibrosis regression from IMPACT 24-week data.
- Additional poster presentations will cover 24-week findings on non-invasive tests and cardiovascular measures.
- The EASL Congress 2026 will take place from May 27-30 in Barcelona, Spain.
- The IMPACT Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3.
- Participants received weekly subcutaneous pemvidutide doses at 1.2 mg, 1.8 mg, or placebo for 48 weeks.
Price Impact
More from ALT